Knewe Biosystems Limited (KBL) 



  Castlemain Capital  

The law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors make an informed decision.

If you are a wholesale investor under the definition of that term in clause 3 of Part 1 Schedule 1 of the Financial Markets Conduct Act 2013, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.

You will also have fewer other legal protections for these investments. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.


The opportunity exists for wholesale investors to express interest in an in an investment in Knewe Biosystems Limited (KBL). KBL is an unlisted, AIC registered, animal prebiotic supplementation company where the key people hold over 150 years collective experience in science, dairy and farming. The company has been granted patents in New Zealand, Australia, Europe, the UK and North America and with good prospects of future growth, is now raising the capital needed to take the business to the next stage of commercialisation.

The product:

Feeding Knewe products will reduce greenhouse emissions from the animals it is fed to, improve the welfare of animals that eat it, and importantly, provide economic benefits for farmers who feed the product to their stock. Knewe-mg is made from by-products of industrial fermentation.

Benefits include:

  • Improvement of feed utilisation by up to 20%
  • Helps increase an animals overall wellbeing
  • Reduces disease issues
  • Lowers an animals greenhouse gas emissions, and aids in reducing nitrogen losses to groundwater
  • Has measurable economic effects for farmers
  • Has multinational patents

Knewe now seeks to raise, via this convertible note, further working capital of $NZ600,000 to assist funding the budgeted rapid growth in the New Zealand and UK markets. The projected financials for that rapid growth are provided in the document accessibke in the Documents section. During that budget period the group will seek to raise further capital by way of a new ordinary share issue, which is expected to be launched towards the end of 2022. Funds received from the new share issue will allow Knewe to complete its plans for successful global commercialisation of Knewe®-Mg The proposed new share offer will give investors an opportunity to purchase Knewe shares at a reasonable price prior to the projected global growth phase of the Knewe business.

Investment Terms

Offer Amount: $NZ600,000 by way of an issue of new unsecured Convertible Notes (“CN’s”).

Issue Price: $1.00 per Note

Minimum Investment: 25,000 Notes ($NZ 25,000)

Term: 24 months from purchase. Redeemable by way of cash or ordinary shares in Knewe at the Investors discretion

Coupon: 7.0% per annum. Payable in arrears on a quarterly basis.

NB the Board of Knewe has since decided, to lift the interest rates on the twenty four month Convertible Unsecured Note from the 7.0% to the following rates:

Up to $25,000       7.85%. p.a.

$25,000 to $50,000  8.50%. p.a.

$50,000 and over    9.85%. p.a.

For further information On the KBL offer, view the flyer in the documents tab.

Issue Type:
isEOI: true

Investment Details

Investment Type: Wholesale

Wholesale Investment Type: NZ Wholesale Equities

Transaction Size:NZD 600,000.00

Committed Capital: 

Pre-money valuation: 

Minimum Capital Raise: 

Share Price:NZD 0.00

Unit Price:NZD 1.00

Minimum Investment Size:NZD 25,000.00

Document Name Description Date Uploaded
Convertible note information pack July 2021 final 5 August 2021 Preview/Download
Zoom: 0

You do not have any investments to report on.

No trade history available for this issue.

Secondary Market - Knewe Biosystems Limited (KBL) Wholesale

No secondary market listings for this issue availble at this time. Check the Exchange for more listings.